Skip to main content
NCBI home page
British Journal of Experimental Pathology logoLink to British Journal of Experimental Pathology
. 1988 Oct;69(5):685–695.

Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.

Q Dong 1, M H Zhou 1, V Subbarao 1, C H Ts'ao 1
PMCID: PMC2013274  PMID: 3143395

Abstract

We determined plasminogen activator (PA) and PA inhibitor (PAI) activities in the intra- and extracellular compartments of an experimental pancreatic ascites tumour with indirect and direct functional assays, and partially characterized these activities on SDS-polyacrylamide gels coupled with fibrin and reverse fibrin autography. Intact tumour cells caused lysis of plasminogen-rich but not plasminogen-free fibrin clots, and the extent of lysis of the former was related to tumour cell count. Direct assay of PA with a synthetic substrate yielded an equivalent of 109 urokinase units per 10(9) tumour cells. No PAI activity was demonstrated in tumour cells with functional assays. Contrary to tumour cells, cell-free ascitic fluids caused no lysis of fibrin clots. Instead, it inhibited tumour cell- and urokinase-induced, but not plasmin-induced, clot lysis in a dose-dependent fashion. Although functional assays failed to demonstrate PA in ascitic fluid and PAI in tumour cells, both activities were detected in electrophoresed samples of cell lysates and fluids by fibrin and reverse fibrin autography. In tumour cells, a mixture of tissue-type PA (tPA) and urokinase-type PA (uPA) were present. In the fluid, uPA together with two other PAs with greater molecular weights than tPA were detected.

Full text

PDF
685

Images in this article

691Fig. 6
on p.691
692Fig. 7
on p.692

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blasi F., Vassalli J. D., Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987 Apr;104(4):801–804. doi: 10.1083/jcb.104.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burgess-Wilson M. E., Cockbill S. R., Johnston G. I., Heptinstall S. Platelet aggregation in whole blood from patients with Glanzmann's thrombasthenia. Blood. 1987 Jan;69(1):38–42. [PubMed] [Google Scholar]
  3. Carroll R. C., Gerrard J. M., Gilliam J. M. Clot retraction facilitates clot lysis. Blood. 1981 Jan;57(1):44–48. [PubMed] [Google Scholar]
  4. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  5. Duffy M. J., O'Grady P. Plasminogen activator and cancer. Eur J Cancer Clin Oncol. 1984 May;20(5):577–582. doi: 10.1016/0277-5379(84)90001-4. [DOI] [PubMed] [Google Scholar]
  6. Eaton D. L., Baker J. B. Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator/antiplasmin. J Cell Biol. 1983 Aug;97(2):323–328. doi: 10.1083/jcb.97.2.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Erickson L. A., Lawrence D. A., Loskutoff D. J. Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem. 1984 Mar;137(2):454–463. doi: 10.1016/0003-2697(84)90113-1. [DOI] [PubMed] [Google Scholar]
  8. Granelli-Piperno A., Vassalli J. D., Reich E. Secretion of plasminogen activator by human polymorphonuclear leukocytes. Modulation by glucocorticoids and other effectors. J Exp Med. 1977 Dec 1;146(6):1693–1706. doi: 10.1084/jem.146.6.1693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Greaves M. F., Chan L. C., Furley A. J., Watt S. M., Molgaard H. V. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 1986 Jan;67(1):1–11. [PubMed] [Google Scholar]
  10. Greineder D. K., Connorton K. J., David J. R. Plasminogen activator production by human monocytes. I. Enhancement by activated lymphocytes and lymphocyte products. J Immunol. 1979 Dec;123(6):2808–2813. [PubMed] [Google Scholar]
  11. Gross J. L., Behrens D. L., Mullins D. E., Kornblith P. L., Dexter D. L. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res. 1988 Jan 15;48(2):291–296. [PubMed] [Google Scholar]
  12. Iwakawa A., Tanaka K. Effect of fibrinolysis inhibitor and chemotherapeutics on the growth of human cancers transplanted into nude mice and in tissue culture. Invasion Metastasis. 1982;2(4):232–248. [PubMed] [Google Scholar]
  13. Keski-Oja J., Vaheri A. The cellular target for the plasminogen activator, urokinase, in human fibroblasts - 66 000 dalton protein. Biochim Biophys Acta. 1982 Apr 29;720(2):141–146. doi: 10.1016/0167-4889(82)90005-2. [DOI] [PubMed] [Google Scholar]
  14. Kopitar M., Rozman B., Babnik J., Turk V., Mullins D. E., Wun T. C. Human leucocyte urokinase inhibitor--purification, characterization and comparative studies against different plasminogen activators. Thromb Haemost. 1985 Dec 17;54(4):750–755. [PubMed] [Google Scholar]
  15. Laug W. E., DeClerck Y. A., Jones P. A. Degradation of the subendothelial matrix by tumor cells. Cancer Res. 1983 Apr;43(4):1827–1834. [PubMed] [Google Scholar]
  16. Liotta L. A. Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986 Jan;46(1):1–7. [PubMed] [Google Scholar]
  17. Peterson H. Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumours. Cancer Treat Rev. 1977 Sep;4(3):213–217. doi: 10.1016/s0305-7372(77)80025-x. [DOI] [PubMed] [Google Scholar]
  18. Rijken D. C., Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981 Jul 10;256(13):7035–7041. [PubMed] [Google Scholar]
  19. Saksela O., Hovi T., Vaheri A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. J Cell Physiol. 1985 Jan;122(1):125–132. doi: 10.1002/jcp.1041220119. [DOI] [PubMed] [Google Scholar]
  20. Saksela O., Vaheri A., Schleuning W. D., Mignatti P., Barlati S. Plasminogen activators, activation inhibitors and alpha 2-macroglobulin produced by cultured normal and malignant human cells. Int J Cancer. 1984 May 15;33(5):609–616. doi: 10.1002/ijc.2910330510. [DOI] [PubMed] [Google Scholar]
  21. Szczepański M., Lucer C., Zawadzki J., Tołoczko T. Procoagulant and fibrinolytic activities of gastric and colorectal cancer. Int J Cancer. 1982 Sep 15;30(3):329–333. doi: 10.1002/ijc.2910300312. [DOI] [PubMed] [Google Scholar]
  22. Ts'ao C., Galluzzo T. S., Hart S. J., Ng A. S., Sorenson P. G., Subbarao V. Anticoagulant activity in cell-free peritoneal fluid of an experimental pancreatic ascites tumor. Thromb Haemost. 1985 Dec 17;54(4):768–772. [PubMed] [Google Scholar]
  23. Unkeless J. C., Gordon S., Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med. 1974 Apr 1;139(4):834–850. doi: 10.1084/jem.139.4.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Unkeless J., Dano K., Kellerman G. M., Reich E. Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator. J Biol Chem. 1974 Jul 10;249(13):4295–4305. [PubMed] [Google Scholar]
  25. Vassalli J. D., Reich E. Macrophage plasminogen activator: induction by products of activated lymphoid cells. J Exp Med. 1977 Feb 1;145(2):429–437. doi: 10.1084/jem.145.2.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wang B. S., McLoughlin G. A., Richie J. P., Mannick J. A. Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines. Cancer Res. 1980 Feb;40(2):288–292. [PubMed] [Google Scholar]
  27. Zucker S., Mehling K., Rai K. Plasminogen-dependent fibrinolytic activity in normal human lymphocytes: diminished lymphocyte plasminogen activator in chronic lymphocytic leukemia. Am J Hematol. 1985 Aug;19(4):373–386. doi: 10.1002/ajh.2830190408. [DOI] [PubMed] [Google Scholar]

Articles from British journal of experimental pathology are provided here courtesy of Wiley

RESOURCES